Threshold Pharmaceuticals, Inc. (THLD: Quote) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.
Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.
Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.
"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.
Click here to receive FREE breaking news email alerts for Threshold Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org